S-735 : Still Just a Bill

The "Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025" (S. 735) aims to improve the prevention and treatment of sickle cell disease and its complications. Key provisions include:

• Reauthorization of a Program: It reauthorizes a sickle cell disease prevention and treatment demonstration program under the Public Health Service Act.
• Expanded Focus: The bill broadens the scope of the program to include not only the treatment of sickle cell disease but also the prevention and treatment of its complications.
• Grant Flexibility: It allows the program to award grants, in addition to contracts and cooperative agreements, to entities working on sickle cell disease.
• Increased Funding: The legislation increases the authorized funding for the program to $8,205,000 per year for fiscal years 2025 through 2029, up from $4,455,000 in previous years.
• Sense of Congress: Expresses the sense of Congress that further research should be conducted to better understand and find cures for heritable blood disorders, including sickle cell disease.